75 results about "Acute myocardial ischaemia" patented technology

The invention discloses a medicine combination of snakegourd peel extract and allium macrostemon extract. The medicine combination is composed of 50-90 parts of snakegourd peel extract and 10-50 parts of allium macrostemon extract by weight; wherein, the total amino acid content in the snakegourd peel extract is not less than 50 percent, if calculated according to arginine, and the total saponin content in the allium macrostemon extract is not less than 50 percent, if calculated according to dioscin. The combination has stable quality, and high content of effective ingredients; the technique of the preparation method of the invention is stable, and has good reproduction quality. Proved by pharmacological tests, the combination has better protective effect on acute myocardial ischemia caused by rat hypophysin and canine myocardial ischemia due to coronary artery ligation. The medicine combination of the invention has promising application prospect in the respect of treating cardiovascular system diseases.

The invention relates to the field of biological imaging agents, in particular to the use of carbon-11 marked N-methyldopamine hydrochloride in the preparation of a positron medicinal imaging agent. The positron medicinal imaging agent can be used as an organism dynamic imaging agent or a fault imaging agent to display cardiac adrenergic absorption, distribution and metabolic process in a heart disease state and the change law of the sympathetic nerve in a disease state. The 11C-N-CH3-Dopamine imaging is more flexible in estimation of serious degree of acute myocardial ischemia and the reversibility of dysautonomia of patients than N-13-amimmon myocardial blood flow perfusion and has an after-ischemia memory effect and thus provides a strong evidence for the early diagnosis and treatment of heart diseases. The invention can be used for early estimation of myocardial ischemia.

A patient monitor for determining a probability that a patient has acute cardiac ischemia including an input device connectable to a patient to acquire electrocardiogram (ECG) signals from the patient, an instrumentation amplifier connected to the input terminal to combine the signals and to generate at least one ECG lead, and an analysis module. The analysis module is operable to continuously read the ECG lead, to analyze a portion of the ECG lead for a period of time, and to calculate a probability that the patient has acute cardiac ischemia based at least in part on the analyzed portion of the ECG lead.

Through experiments, the invention proves applications of a cape jasmine and a cape jasmine extract product in the preparation of drugs for treating myocardial infarction, coronary heart disease, myocardial ischemia and cardiac arrhythmia, especially to an application in treatment of acute myocardial ischemia or myocardial ischemia of coronary heart disease caused by restenosis after percutaneous transluminal coronary angioplasty (PTCA). In addition, it is proved through experiments that the above various kinds of applications are accomplished by protection of cardiac muscle and cardiac muscle cell from damage or resistance against inflammatory lesion and oxidative damage of cardiac muscle cell. And an effective dose of cape jasmine and the cape jasmine extract product in a unit preparation is obtained by detection.

The present invention is schefflera venulosa extract and its preparation process and use in preparing medicine. The schefflera venulosa extract contains mainly caffeoyl acids 5-40 wt%, quercetin glycoside 15-55 wt% and oleanolic acid glycoside 15-45 wt%. The schefflera venulosa extract may be prepared into orally taken preparation or injection alone or together with pharmaceutically acceptable supplementary material, and the medicine preparation may be used in promoting blood circulation to disperse blood clots, improving microcirculation, and preventing and treating acute myocardial ischemia, coronary heart disease, angina pectoris and other cardiac and cerebral vascular diseases.

A Chinese medicine for treating ischemic cardiovascular and cerebrovascular diseases is prepared from 3 Chinese-medicinal materials ginseng, red sage root and corydalis tuber through extracting, separating by adsorptive resin, eluting and concentrating. Its advantages are high curative effect and low cost.

The invention discloses a snakegourd fruit vegetable protein beverage and a preparation method thereof, wherein the snakegourd fruit vegetable protein beverage comprises components with parts by weight: snakegourd fruit seed kernel meal 30-40 parts, citrus 3-5 parts, honeysuckles 4-5 parts, chrysanthemums 3-6 parts, acidulants 1-2 parts, flavouring agents 2-3 parts, vitamin C 6-10 parts, grape juice 10-12 parts, sweetening agents 2-4 parts, emulgator 1-1.5 parts, stabilizers 2-3 parts and water 60-80 parts. The method for preparing the snakegourd fruit vegetable protein beverage comprises steps: pretreatment of raw materials, defibrination, melting and mixing materials, constant volume, double homogeneous treatment, heating, filling, sterilization, concentration and packaging. Compared with the prior art, the snakegourd fruit vegetable protein beverage and the preparation method thereof have the beneficial effects that the snakegourd fruit vegetable protein beverage is high in protein content, low in fat content, high in nutritive value and better in taste, has obvious anti-hyperlipid and anti-thrombus effects, resists acute myocardial ischemia, reduces blood, enhances human immunity, delays senescence, soothes the nerves and nourishes and the like, is complete in care functions, and has the effects of discharging toxification and lubricating the intestines, beautifying the features and keeping fit.

Low-viscosity, high concentration nucleic acid compositions that can be administered by multiple parenteral routes may allow for less frequent dosing than nucleic acid products currently on the market. In particular, low-viscosity defibrotide formulations for subcutaneous, intramuscular, and intraperitoneal administration are more convenient to the patient and/or are administered outside of the hospital setting. Formulations of the invention may be used for the treatment of numerous conditions including for example, treatment of peripheral arteriopathies, treatment of acute renal insufficiency, treatment of acute myocardial ischemia, and treatment and prevention of sinusoidal obstruction syndrome or VOD.

A method for producing paeonoside metabolic hormone-I by fermenting short Lactobacillus is carried out by inducing L.brevis AS 1.12 into culture medium with tomato juice 200g/L, protein peptone 7.5g/L, yeast paste 7.5g/L, glucose 10g/L, Tween-80 0.3 ml/L and pH=7.0-8.5, anaerobic culturing at 25-37 degree for 12-24 hrs, centrifugal collecting bacterial cells, washing by normal saline, centrifuging, dispersing obtained cells into buffer liquid of 0.05M phosphate, adding into substrate paeonoside or its analogs hydroxy-paeonoside or methyl-paeonoside or benzoyl-paeonoside or mixture of paeonoside and its analogs, converting at 30-40 degree for 2-24 hrs, extracting by ethyl acetate, drying concentrated extract to obtain concrete, chromatographying by silica-gel column to obtain final product. It's simple, cheap, efficient, fast and controllable and has friendly environment. It can be used for anti-inflammatory, stress ulcer, analgesic and antispasmodic, ecstatic coronary blood vessel, myocardial ischemia and platelet aggregation-inhibition.

The invention relates to the new usage of formononetin-3'-sodium sulfonate, and provides the application of the formononetin-3'-sodium sulfonate in the preparation of medicine for treating or preventing cardiovascular disease. The invention more particularly relates to the application of the formononetin-3'-sodium sulfonate in the preparation of medicine for treating or preventing coronary heart disease, angina pectoris or myocardial infarction. The formononetin-3'-sodium sulfonate remarkably reduces the rise of acute myocardial ischaemia rat limb lead electrocardiogram J point, and the ischemic area.

The invention relates to a ferulic acid calcium injection and a preparation method thereof. The injection has the following components according to parts by weight: 1 part of ferulic acid calcium, 0-100 parts of injection additive. The invention provides a new ferulic acid salt injection and a preparation thereof, which obviously inhibits platelet aggregation induced by ADF and improves acute myocardial ischemia caused by pituitrin.

The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing cardiac ischemia. In a specific embodiment, a method for diagnosing acute cardiac ischemia in a patient comprises the steps of (a) measuring the levels of one or more post-translationally modified and unmodified serum albumin peptides in a sample collected from the patient using SRM-MS, wherein the post-translationally modified peptides are phosphorylated and/or cysteinylated; (b) comparing the levels of the measured one or more post-translationally modified serum albumin peptides to the levels of the measured one or more unmodified serum albumin peptides; and (c) correlating the compared levels to a patient having ACI or to a patient not having ACI, thereby providing the diagnosis.

A Chinese medicine for treating coronary heart disease is prepared from 14 Chinese-medicinal materials including astragalus root, pilose asiabell root, fleece flower root, red sage root, etc through extracting, concentrating, spray drying, adding auxiliary and shaping.

Belonging to the field of medicine, the invention relates to application of a qi regulating and blood activating preparation in preparation of a drug for prevention and treatment of acute coronary syndrome. The qi regulating and blood activating preparation is prepared from 350-600 parts of Cinnamomum migao, 4-15 parts of borneol, 250-500 parts of Ligusticum wallichii, 25-50 parts of Allium macrostemon as the raw materials. Clinical experiments investigate patient angina pectoris, traditional Chinese medicine syndrome scoring, inflammatory indicators and other indexes, and experimental data show that the qi regulating and blood activating preparation can protect blood vessel injury, control inflammatory reaction and alleviate plaque formation and rupture, can significantly improve acute myocardial infarction caused by acute myocardial ischemia, unstable angina and other symptoms. Thus, the qi regulating and blood activating preparation can be used as an ideal drug for prevention and treatment of acute coronary syndrome.

Fructosylated puerarin being converted from puerarin by a bioconversion method conducted in an aqueous phase or nonaqueous phase system, including monofructosyl-(2,6)-puerarin, bifructosyl-(2,6)-puerarin, trifructosyl-(2,6)-puerarin, tetrafructosyl-(2,6)-puerarin and pentafructosyl-(2,6)-puerarin. Tests have shown that the oligosaccharylated puerarin is effective to treat acute myocardial ischemia, and can markedly suppress in vitro the proliferation of human breast cancer cell strain MDA-MB-23 and human chronmyelogenors leukemia cell strain K562, and it has a low toxicity.

Described herein are compounds, compositions and methods for modification of the surface of a living cell with a therapeutically relevant targeting moiety. Also described herein are methods for treating disease states, such as acute myocardial ischemia or infarction, with said compositions, in a subject.

The invention discloses a pharmaceutical composition and preparation and applications thereof in treating coronary heart disease and angina pectoris. The pharmaceutical composition comprises the following raw medicines in parts by weight: 15-21 parts of kudzu root, 15-21 parts of yam and 15-21 parts of ginkgo leaf. The pharmaceutical composition is prepared by the following steps of: pretreating the raw medicines, crushing, extracting by reflux with 50-70% ethanol, filtering, combining the ethanol extraction solutions, concentrating at 55-65 DEG C until the relative density is 1.15-1.17, cooling and drying to obtain the pharmaceutical composition in a dry powder state. The pharmaceutical composition and pharmaceutically acceptable auxiliary materials can be prepared into granules, capsules, pills, dripping pills, powder, soluble granules and tablets. The pharmaceutical composition preparation in any dosage form is applied to treatment of coronary heart disease and angina pectoris. The pharmaceutical composition disclosed by the invention has reasonable compatibility and high utilization rate of active ingredients, has an obvious effect on acute myocardial ischemia, has an obvious inhibiting effect on thrombosis of the arteriovenous shut, enhances the hypoxia tolerance ability of a body, promotes the restoration of cardiac functions, is safe, and has low toxicity. Proven by clinical tests, the pharmaceutical composition has obvious therapeutic effects on coronary heart disease and angina pectoris.

The invention discloses a medical application of fragrant solomonseal rhizome polysaccharide, which is characterized by the following: resisting acute myocardial ischemia; lessening the degree of myocardial infarction obviously; reducing the scale and area of myocardial infarction and the release of myocardial enzyme; adopting the fragrant solomonseal rhizome polysaccharide to mate medically acceptable drug agent to do real usage.

The invention belongs to a field of medicament preparation, and relates to a pharmaceutical composition for treating cardiovascular disease and a preparation method thereof, especially to the pharmaceutical composition which contains drug-efficacy component groups capable of being absorbed into blood. The drug-efficacy component groups comprise: Japanese bufotaline, ginsenoside Re, ginsenoside Ra1, 1[beta]-hydroxy bufalin, ginsenoside Rb1, resibufogenin fine alcohol, ginsenoside Rc, ginsenoside Rb2, ginsenoside, ginsenoside Rd, bufalin, cholic acid, hyodeoxy cholic acid, cinobufagin, chenodeoxycholic acid and deoxycholic acid. The medicament has clear in vivo targets, has characteristics and advantages of multi-component multi-target effects, is good in protective effects for acute myocardial ischemia, and can reduce area of myocardial infarction and content of Lactate dehydrogenase and creatine kinase in serum.

The invention discloses flavored snakegourd fruit juice. The flavored snakegourd fruit juice is prepared from, by weight, 65-75 parts of snakegourd peel, 8-10 parts of liquorice roots, 9-15 parts of mint, 6-10 parts of hawthorn fruits, 10-12 parts of radix angelica sinensis, 12-15 parts of aloe juice, 9-15 parts of xanthan gum, 4-9 parts of sodium alginate, 5-12 parts of citric acid, 7-10 parts of malic acid, 6-8 parts of vitamin C, 18-25 parts of honey, 3-5 parts of salt, 5-10 parts of potassium sorbate, 6-12 parts of ethyl maltol, 3-5 parts of hydroxyethyl cellulose and the balance water. Compared with the prior art, the flavored snakegourd fruit juice has the advantages that the processing process is simple, and cost is low; the flavored snakegourd fruit juice is high in protein content, high in nutritional value and good in taste, and has the remarkable healthcare effects of resisting hyperlipidemia, thrombi and acute myocardial ischemia, reducing blood pressure, enhancing the immunity of the human body, delaying aging, soothing the nerves, achieving nourishment and the like, and comprehensive healthcare functions are achieved.

The invention discloses a hilicidum injection for preventing and treating ischemic cardiovascular and cerebrovascular diseases as well as a preparation method and application thereof. The injection comprises 20-2000 parts of hilicidum, 40-4000 parts of cosolvent, 18-900 parts of sodium chloride and the balance of water by weight. The preparation method is characterized by comprising the following steps: taking water for injection, adding the cosolvent, stirring the cosolvent to completely dissolve the cosolvent, then adding hilicidum, stirring the solution until the solution is clear and transparent, then adding sodium chloride and activated carbon, stirring the solution, filtering the solution to remove carbon, adding the water for injection and carrying out filtration, filing and sterilization, thus obtaining the hilicidum injection. The hilicidum injection is applied to medicines for preventing and/or treating ischemic cardiovascular and cerebrovascular diseases. The hilicidum in the hilicidum injection can obviously reduce the volume of global ischemic and focal ischemic cerebral infarction, is used for preventing and treating ischemic cerebral infarction, can obviously lower a J point of a limb lead electrocardiogram of rats with acute myocardial ischemia and reduce the ischemic area and can be used for preventing and treating ischemic myocardial infarction.

The invention discloses a traditional Chinese medicine substance composition and a myocardial ischemia resisting effect thereof. The traditional Chinese medicine substance composition disclosed by the invention is obtained by extracting heart tonifying soup with ethanol and purifying with macroporous adsorption resin, and phenol and triterpenoid saponin ingredients in the heart tonifying soup are enriched; meanwhile, proved by experiments on rats with acute myocardial ischemia, the traditional Chinese medicine drug substance composition has an obvious myocardial ischemia resisting effect, and after prophylactic administration, the content of serum creatine kinase and lactate dehydrogenase in blood serum of model rats can be lowered.

The invention discloses an application of secnidazole to preparation of drugs for treating and/or preventing myocardial ischemia. The invention further discloses a pharmaceutical composition for treating and/or preventing the myocardial ischemia. The pharmaceutical composition comprises the secnidazole and a pharmaceutically acceptable excipient. A pharmacodynamic experiment result shows that thesecnidazole has a protective effect on an experimental myocardial ischemic injury, can significantly reduce the area of myocardial infarction, reduce the degree of myocardial damage, reduce the MDA content in serum and increase the content of active SOD, and can effectively resist acute myocardial ischemia and protect myocardium, so as to improve the symptoms of the myocardial ischemia.